NYT: Duke Univ. scandal shed light on flawed multi-gene cancer test

The New York Times has a story today that paints a damning portrait of life sciences researchers and companies that are rushing toward market with molecular tests for cancer before the tests have proven their value in helping fight cancer--sometimes with tragic consequences for patients who put their faith in the diagnostics. The story's unfortunate poster child of the problem is a Duke University multi-gene test for predicting effective drugs against cancer that was eventually found to be ineffective. Statisticians at MD Anderson Cancer Center found the bugs in the Duke test, but the flaws didn't gain wide attention until it came to light last year that one of the Duke cancer researchers behind the test falsified his resume. Story

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spin-out company SpringWorks has lost president and founder Lara Sullivan, M.D. who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.